Artificial intelligence in genitourinary oncology: publication trends and systematic review
BJU International · 2026
DOI: 10.1111/bju.70361 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BJU International, 2026. Verfasst von Alee Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: The University of Oklahoma College of Medicine, Oklahoma City, OK, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Urogenital Neoplasms, Medical Oncology. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To conduct an analysis of publication trends and a systematic review of randomized controlled trials (RCTs) to characterize the current state of artificial intelligence (AI) use in genitourinary (GU) oncology, as AI has emerged as a transformative tool in healthcare with potential applications in diagnostics, treatment planning, and prognostication.
Methods
We searched the Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE; Ovid), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) Ultimate for studies related to AI and GU oncology, excluding non‐English papers, non‐human studies, review articles, and articles using AI solely for manuscript writing. Publication trends were analysed from 2013 to 2023 and categorized by study design and cancer type. RCTs were evaluated through systematic review using Covidence (Veritas Health Innovation Ltd, Melbourne, Victoria, Australia) for screening and data extraction. Two reviewers independently assessed all studies, with risk of bias (RoB) evaluated using the Cochrane RoB 2.0 tool.
Results
Of 2409 articles identified, 1220 met inclusion criteria. These included 962 retrospective articles, 175 prospective studies, 79 studies with combined retrospective/prospective methods, and four RCTs. Studies most commonly addressed prostate ( n = 923), renal ( n = 274), and urothelial ( n = 194) cancers. Publications grew from 14 in 2013 to 362 in 2023, with substantial acceleration in 2019. Four RCTs were identified – one in urothelial cancer and three in prostate cancer. Two RCTs evaluated AI‐based diagnostics, demonstrating improved performance over conventional methods; the remaining two RCTs evaluated AI in prognostication and treatment planning, showing improved gains in imaging interpretation and operational efficiency. RoB varied across studies, primarily related to randomisation and deviations from intended interventions.
Conclusions
Artificial intelligence research in GU oncology has grown, although high‐level evidence from RCTs remains limited. Existing trials underscore AI's promise in diagnostics, prognostication, and treatment planning, and the rapidly evolving nature of this field warrants continued prospective investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
ORCID-Profile: Alee Kim, Nicole A Moore
Zitieren
APA
Kim, A., Moore, N. A., Dong, T., Fu, K., Keyser, K., Clifton, S., Ayanambakkam, A., & Nipp, R. (2026). Artificial intelligence in genitourinary oncology: publication trends and systematic review. BJU International. https://doi.org/10.1111/bju.70361
Vancouver
Kim A, Moore NA, Dong T, Fu K, Keyser K, Clifton S, et al. Artificial intelligence in genitourinary oncology: publication trends and systematic review. BJU International. 2026. doi:10.1111/bju.70361
BibTeX
@article{Kim2026,
author = {Kim, Alee and Moore, Nicole A and Dong, Tammy and Fu, Kelsy and Keyser, Katie and Clifton, Shari and Ayanambakkam, Adanma and Nipp, Ryan},
title = {Artificial intelligence in genitourinary oncology: publication trends and systematic review},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70361}
}
EUVIMED